TGF-β mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells

Cancer Research

Volumn 73, Issue 7, 2013, Pages 2333-2344

  Shinojima, Naoki ^a,b   Hossain, Anwar ^a   Takezaki, Tatsuya ^a,b   Fueyo, Juan ^a   Gumin, Joy ^a   Gao, Feng ^a   Nwajei, Felix ^a   Marini, Frank C ^a   Andreeff, Michael ^a   Kuratsu, Jun Ichi ^b   Lang, Frederick F ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; ONCOLYTIC ADENOVIRUS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STEM CELL; CELL HOMING; CELL MIGRATION; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY DEVICE; DRUG TARGETING; GENE SILENCING; GLIOBLASTOMA; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TROPISM; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLIOMA; HUMANS; MESENCHYMAL STROMAL CELLS; NEOPLASTIC STEM CELLS; RATS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875972297     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3086     Document Type: Article

References (46)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
2. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003;3:90-105, 151.
3. Decleves X, Amiel A, Delattre JY, Scherrmann JM. Role of abc transporters in the chemoresistance of human gliomas. Curr Cancer Drug Targets 2006;6:433-45.
4. Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus delta24-rgd to human gliomas. Cancer Res 2009;69:8932-40.
5. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307-18.
6. Hata N, Shinojima N, Gumin J, Yong R, Marini F, Andreeff M, et al. Platelet-derived growth factor bb mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery 2010;66:144-56; discussion 156-7.
7. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007;13:5020-7.
8. Birnbaum T, Roider J, Schankin CJ, Padovan CS, Schichor C, Goldbrunner R, et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 2007;83:241-7.
9. Doucette T, Rao G, Yang Y, Gumin J, Shinojima N, Bekele BN, et al. Mesenchymal stem cells display tumor-specific tropism in an rcas/ntv - a glioma model. Neoplasia 2011;13:716-25.
10. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004; 432:396-401.
11. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010;17:362-75.
12. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84.
13. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting wnt, notch, and hedgehog pathways. Nat Rev Clin Oncol 2011;8:97-106.
14. Maitland NJ, Collins AT. Cancer stem cells - a therapeutic target? Curr Opin Mol Ther 2010;12:662-73.
15. Binello E, Germano IM. Stem cells as therapeutic vehicles for the treatment of high-grade gliomas. Neuro Oncol 2012;14:256-65.
16. Oh MC, Lim DA. Novel treatment strategies for malignant gliomas using neural stem cells. Neurotherapeutics 2009;6:458-64.
17. Pohlers D, Brenmoehl J, Loffler I, Muller CK, Leipner C, Schultze-Mosgau S, et al. Tgf-beta and fibrosis in different organs - molecular pathway imprints. Biochim Biophys Acta 2009;1792:746-56.
18. Dvorak HF. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-9.
19. Schneider T, Sailer M, Ansorge S, Firsching R, Reinhold D. Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma. J Neurooncol 2006;79:61-5.
20. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, et al. High tgfbeta-smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the pdgf-b gene. Cancer Cell 2007;11:147-60.
21. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. Autocrine tgf-beta signaling maintains tumorigenicity of glioma-initiating cells through sry-related hmg-box factors. Cell Stem Cell 2009;5:504-14.
22. Strege RJ, Godt C, Stark AM, Hugo HH, Mehdorn HM. Protein expression of fas, fas ligand, bcl-2 and tgfbeta2 and correlation with survival in initial and recurrent human gliomas. J Neurooncol 2004;67: 29-39.
23. Penuelas S, Anido J, Prieto-Sanchez RM, Folch G, Barba I, Cuartas I, et al. Tgf-beta increases glioma-initiating cell self-renewal through the induction of lif in human glioblastoma. Cancer Cell 2009;15:315-27.
24. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
25. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of tgf-beta signaling. Proc Natl Acad Sci U S A 2007;104:3460-5.
26. Setoguchi T, Taga T, Kondo T. Cancer stem cells persist in many cancer cell lines. Cell Cycle 2004;3:414-5.
27. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the c6 glioma cell line. Proc Natl Acad Sci U S A 2004;101:781-6.
28. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc 2006;1:241-5.
29. Oh CD, Maity SN, Lu JF, Zhang J, Liang S, Coustry F, et al. Identification of sox9 interaction sites in the genome of chondrocytes. PLoS One 2010;5:e10113.
30. Walder RY, Garrett MR, McClain AM, Beck GE, Brennan TM, Kramer NA, et al. Short tandem repeat polymorphic markers for the rat genome from marker-selected libraries. Mamm Genome 1998;9:1013-21.
31. Masek T, Vopalensky V, Suchomelova P, Pospisek M. Denaturing rna electrophoresis in tae agarose gels. Anal Biochem 2005;336:46-50.
32. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest 1990;86:1976-84.
33. Olmsted-Davis EA, Gugala Z, Gannon FH, Yotnda P, McAlhany RE, Lindsey RW, et al. Use of a chimeric adenovirus vector enhances bmp2 production and bone formation. Hum Gene Ther 2002;13:1337-47.
34. Kollar K, Cook MM, Atkinson K, Brooke G. Molecular mechanisms involved in mesenchymal stem cell migration to the site of acute myocardial infarction. Int J Cell Biol 2009;2009:904682.
35. Kode JA, Mukherjee S, Joglekar MV, Hardikar AA. Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 2009;11:377-91.
36. Giannone G, Dubin-Thaler BJ, Rossier O, Cai Y, Chaga O, Jiang G, et al. Lamellipodial actin mechanically links myosin activity with adhesion-site formation. Cell 2007;128:561-75.
37. Ladwein M, Rottner K. On the rho'd: the regulation of membrane protrusions by rho-gtpases. FEBS Lett 2008;582:2066-74.
38. Menicanin D, Bartold PM, Zannettino AC, Gronthos S. Genomic profiling of mesenchymal stem cells. Stem Cell Rev 2009;5:36-50.
39. Bierie B, Moses HL. Tumour microenvironment: Tgfbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506-20.
40. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in t cells. Nat Med 2001;7:1118-22.
41. Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, et al. Tgf-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009;15:757-65.
42. Goldstein RH, Reagan MR, Anderson K, Kaplan DL, Rosenblatt M. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res 2010;70: 10044-50.
43. Zhang F, Tsai S, Kato K, Yamanouchi D, Wang C, Rafii S, et al. Transforming growth factor-beta promotes recruitment of bone marrow cells and bone marrow-derived mesenchymal stem cells through stimulation of mcp-1 production in vascular smooth muscle cells. J Biol Chem 2009;284:17564-74.
44. Hall A. Rho gtpases and the actin cytoskeleton. Science 1998;279: 509-14.
45. Derynck R, Zhang YE. Smad-dependent and smad-independent pathways in tgf-beta family signalling. Nature 2003;425:577-84.
46. Belema-Bedada F, Uchida S, Martire A, Kostin S, Braun T. Efficient homing of multipotent adult mesenchymal stem cells depends on frount-mediated clustering of ccr2. Cell Stem Cell 2008;2: 566-75.